AB SCIEX launches next gen mass spectrometers

Updated on 25 May 2012

With new multi-component IonDrive technology increasing the generation, transmission and detection of ions, the AB SCIEX 6500 series delivers unparalleled sensitivity enhancements

AB SCIEX leverages on IonDrive technology

AB SCIEX 6500 series is suited for a variety of applications, including drug discovery and development in regulated laboratories

Singapore: AB SCIEX, a global leader in life science analytical technologies, has launched Triple Quad 6500 and QTRAP 6500 systems, next-generation mass spectrometers that deliver up to a 10x increase in sensitivity over the best-selling, high-performance triple quadrupole system on the market. With new multi-component IonDrive technology increasing the generation, transmission and detection of more ions, the AB SCIEX 6500 series delivers unparalleled sensitivity enhancements.

This is made possible by significant improvements in the ionization source through the new IonDrive Turbo V source, enhancements in the ion transmission stage with the novel IonDrive QJet guide, and a 20x increase to the detector dynamic range with the IonDrive High Energy detector. These breakthrough advancements were conceived by AB SCIEX's world-class R&D organization to drive more ions through the mass spectrometer than ever possible.

"The AB SCIEX 6500 series represents a quantum leap forward in mass spectrometry quantitation," said Mr Rainer Blair, president of AB SCIEX. "With the first-of-its-kind IonDrive technology that we are pioneering in the new AB SCIEX 6500 system, scientists will be able to quantitate at lower concentration levels than ever before. This is truly game-changing technology, and we expect it to help reinforce AB SCIEX's market leadership."

The AB SCIEX 6500 series is ideally suited for a variety of applications, including drug discovery and development in regulated laboratories; peptide quantitation as well as biomarker verification in biomedical research; and clinical research in endocrinology laboratories. The 6500 platform is also compatible with SelexION Technology, which is novel technology that delivers a new dimension of selectivity in differential ion mobility spectrometry for quantitative and qualitative analysis.

Leave a Reply

Notify me of follow-up comments via e-mail address

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X